Alvocidib (flavopiridol) for the treatment of chronic lymphocytic leukemia

Expert Opinion on Investigational Drugs

Volumn 25, Issue 6, 2016, Pages 729-734

  Wiernik, Peter H ^a  

^a Cancer Research Foundation of New York   (United States)

Author keywords

Alvocidib; chronic lymphocytic leukemia; cytokine release syndrome; flavopiridol; tumor lysis syndrome

Indexed keywords

FLAVOPIRIDOL; ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE; FLAVONOID; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR;

ARTICLE; CANCER CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CYTOKINE RELEASE SYNDROME; DIARRHEA; DRUG EFFICACY; DRUG LEGISLATION; DRUG MARKETING; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MEDICINAL CHEMISTRY; MULTICENTER STUDY (TOPIC); NONHUMAN; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); TUMOR FLARE; TUMOR LYSIS SYNDROME; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; DRUG EFFECTS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CYCLIN-DEPENDENT KINASES; FLAVONOIDS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PIPERIDINES; PROTEIN KINASE INHIBITORS;

EID: 84963998098     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2016.1169273     Document Type: Article

References (49)

1. U.Rozovski, O.Benjamini, P.Jain, et al. Outcomes of patients with chronic lymphocytic leukemia and Richter’s transformation after transplantation failure. J Clin Oncol. 2015;33:1557–1563.
2. P.A.Thompson, S.M.O’Brien, W.G.Wierda, et al. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Cancer. 2015;121:3612–3621.
3. Q.Yang, P.Modi, T.Newcomb, et al. Idelalisib: first-in-class PI3K delta inhibitor for the treatment of chronic lymphocytic leukemia, small lymphocytic leukemia, and follicular lymphoma. Clin Cancer Res. 2015;21:1537–1542.
4. C.S.Zent, X.V.Wang, R.P.Ketterling, et al. A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progress chronic lymphocytic leukemia in older patients: a trial of the ECOG-Acrin Cancer Research Group (E1908). Am J Hematol. 2016;91:308–312.
5. J.C.Byrd, J.Flynn, T.J.Kipps, et al. Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia. Blood. 2016;127:79–86.
6. S.Grosicki Ofatumumab for the treatment of chronic lymphocytic leukemia. Expert Rev Hematol. 2015;8:265–272.
7. D.M.Lucas, A.S.Ruppert, G.Lozanski, et al. Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US Intergroup phase III trial E2997. Leuk Lymphoma. 2015;56:3031–3037.
8. B.D.Cheson, W.Brugger, G.Damaj, et al. Optimal use of bendamustine in hematologic disorders: treatment recommendations from an international consensus panel-an update. Leuk Lymphoma. 2015;23:1–17.
9. S.Lepretre, C.Dartigeas, P.Feugier, et al. Systematic review of the recent evidence for the efficacy and safety of chlorambucil in the treatment of B-cell malignancies. Leuk Lymphoma. 2015;8:1–14.
10. R.Maffei, E.Colaci, S.Fiorcari, et al. Lenalidomide in chronic lymphocytic leukemia: the present and future in the era of tyrosine kinase inhibitors. Crit Rev Oncol Hematol. 2016;97:291–302.• Excellent review of an important drug.
11. L.Shvidel, A.Berrebi. Pitting new treatments for chronic lymphocytic leukemia against old ones: how do they fare? Expert Rev Hematol. 2015;23:1–10.
12. A.W.Roberts, M.S.Davids, J.M.Pagel, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:311–322.
13. J.F.Zeidner, J.E.Karp. Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia. Leuk Res. 2015;39:1312–1318.
14. M.S.Kwak, S.J.Yu, J.H.Yoon, et al. Synergistic anti-tumor efficacy of doxorubicin and flavopiridol in an in vivo hepatocellular carcinoma model. J Cancer Res Clin Oncol. 2015;141:2037–2045.
15. Y.Song, X.Xin, X.Zhai, et al. Sequential combination of flavopiridol with taxol synergistically suppresses human ovarian carcinoma growth. Arch Gyenocol Obstet. 2015;291:143–150.
16. S.Brenner, J.Riha, B.Giessrigl, et al. The effect of organic anion-transporting polypeptides 1B1, 1B3 and 2B1 on the antitumor activity of flavopiridol in breast cancer cells. Int J Oncol. 2015;46:324–332.
17. B.C.Soner, H.Aktug, E.Adikgoz, et al. Induced growth inhibition, cell cycle arrest and apoptosis in CD133+/CD44+ prostate cancer stem cells by flavopiridol. In J Mol Med. 2014;34:1249–1256.
18. H.G.Lee, J.W.Baek, S.J.Shin, et al. Antitumor effects of flavopiridol on human uterine leiomyoma in vitro and in a xenograft model. Reprod Sci. 2014;21:1153–1160.
19. S.K.Jain, S.B.Bharate, R.A.Vishwakarma. Cyclin-dependent kinase inhibition by flavoalkaloids. Mini Rev Med Chem. 2012;12:632–649.• Excellent review of the mechanism of action of this class of drugs.
20. A.M.Senderowicz, D.Headlee, S.F.Stinson, et al. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol. 1998;16:2986–2999.
21. J.C.Byrd, C.Shinn, J.K.Waselenko, et al. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood. 1998;92:3804–3816.•• Landmark demonstration of alvocidib activity in CLL.
22. J.S.Blachly, J.C.Byrd. Emerging drug profile: cyclin-dependent kinase inhibitors. Leuk Lymphoma. 2013;54:2133–2143.
23. C.Pepper, A.Thomas, T.Hoy, et al. Flavopiridol circumvents Bcl-2 family mediated inhibition of apoptosis and drug resistance in B-cell chronic lymphocytic leukaemia. Br J Haematol. 2001;114:70–77.
24. S.R.Hussain, D.M.Lucas, A.J.Johnson, et al. Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium. Blood. 2008;111:3190–3199.
25. E.Mahoney, J.C.Byrd, A.J.Johnson. Autophagy and ER stress play an essential role in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol. Autophagy. 2013;9:434–435.
26. E.Mahoney, D.M.Lucas, S.V.Gupta, et al. ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol. Blood. 2012;120:1262–1273.
27. B.Ray, S.Agarwal, N.Lohani, et al. Structural, conformational and thermodynamic aspects of groove-directed-intercalation of flavopiridol into DNA. J Biomol Struct Dyn. 2016;17:1–18.
28. D.Myatt, L.Johnson, S.Baumli, et al. The binding of flavopiridol to blood serum albumin. Chirality. 2010;22(Suppl 1E):E40–43.
29. W.Ni, J.Ji, Z.Dai, et al. Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition. PLoS One. 2010;5:e13792.
30. D.Cihalova, F.Staud, M.Ceckova. Interactions of cyclin-dependent kinase inhibitors AT-7519, flavopiridol and SNS-032 with ABCB1, ABCG2 and ABCC1 transporters and their potential to overcome multidrug resistance in vitro. Cancer Chemother Pharmacol. 2015;76:105–116.
31. H.Kodaira, H.Kusuhara, J.Ushiki, et al. Kinetic analysis of the cooperation of p-glycoprotein (P- gp/Abeb1) and breast cancer resistance protein (Berp/Abeg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone. J Pharmacol and Exptl Therapeutics. 2010;333:788–796.
32. J.C.Byrd, T.S.Lin, J.T.Dalton, et al. Flaavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood. 2007;109:399–404.•• Important demonstration of the importance of scheduling.
33. M.A.Phelps, T.S.Lin, A.J.Johnson, et al. Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood. 2009;113:2637–2645.
34. D.M.Stephens, A.S.Ruppert, K.Maddocks, et al. Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia. Leuk Res. 2013;37:1195–1199.
35. K.Maddocks, L.Wei, D.Rozewski, et al. Reduced occurrence of tumor flare with flavopiridol followed by combine flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL). Am J Hematol. 2015;90:327–333.
36. J.C.Byrd, B.L.Peterson, J.Gabrilove, et al. Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805. Clin Cancer Res. 2005;11:4176–4181.
37. T.S.Lin, A.S.Ruppert, A.J.Johnson, et al. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol. 2009;27:6012–6018.•• A major Phase II study.
38. R.A.Messmann, C.D.Ulmann, T.Lahusen, et al. Flavopiridol-related proinflammatory syndrome is associated with induction of interleukin-6. Clin Cancer Res. 2003;9:562–570.
39. M.C.Lanasa, L.Andritsos, J.R.Brown, et al. Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia. Leuk Res. 2015;39:495–500.
40. J.F.Zeidner, M.C.Foster, A.L.Blackford, et al. Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia. Haematologica. 2015;100:1172–1179.
41. K.A.Blum, A.S.Ruppert, J.A.Woyach, et al. Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol. Leukemia. 2011;25:1444–1451.
42. J.Ji, D.R.Mould, K.A.Blum, et al. A pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol. Clin Cancer Res. 2013;19:1269–1280.•• An important toxicity study.
43. R.Ali, F.Ozkalemkaş, V.Ozkocaman, et al. Successful labor in the course of chronic lymphocytic leukemia (CLL) and management of CLL during pregnancy with leukaphersis. Ann Hematol. 2004;83:61–63.
44. S.C.Howard, S.Trifilio, T.K.Gregory, et al. Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review. Ann Hematol. 2016;95:563–573.
45. P.H.Wiernik, J.P.Dutcher, A.N.Leaf, et al. Objective response of multiple myeloma to cyclosporine A. Leuk Lymphoma. 1994;16:167–170.
46. G.A.Kennedy, A.Varelias, S.Vuckovic, et al. Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial. Lancet Oncol. 2014;15:1451–1459.
47. X.Yang, X.Zhao, M.A.Phelps, et al. A novel liposomal formulation of flavopiridol. Int J Pharm. 2009;365:170–174.
48. J.A.Woyach, G.Lozanski, A.S.Ruppert, et al. Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features. Leukemia. 2012;26:1442–1444.
49. D.M.Stephens, A.S.Ruppert, K.Blum, et al. Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach. Haematologica. 2012;97:423–427.